Back

dr. M.S. (Marjolein) de Bruin-Weller

dr. M.S. (Marjolein) de Bruin-Weller

Full Professor
dr. M.S. (Marjolein) de Bruin-Weller
  • Dermatology and Allergology

Research Programs

Infection & Immunity

Biography

Biography

Marjolein de Bruin-Weller  is a dermatologist and full professor in atopic dermatitis and head of the National Expertise Center of Atopic Dermatitis,  situated  in the dpt. of Dermatology and Allergology of the University Medical Center of Utrecht, The Netherlands

 

After her training in physiotherapy (1979-1983), she started her medical training at the University of Leiden and graduated in 1990. After this she started as a PhD candidate at Astmacenter Heideheuvel, Hilversum, the Netherlands, supervised by Professor Jan de Monchy (allergologist  University Medical Center Groningen, Professor Henk Jansen (pulmonologist University Medical Center Amsterdam) and dr. Frank Weller (pulmonologist University Medical Center Amsterdam).  In 1997 she defended her PhD thesis “Dynamics of the allergic reaction in the airways and the skin”  at the University of Groningen.

 

She started her training in dermatology in 1997 at the department of Dermatology/Allergology of the University Medical Center Utrecht and became a staff member at this department in 2001, with a special focus on atopic dermatitis.  In October 2018 she was appointed as Associate Professor and in December 2021 as full professor in atopic dermatitis.

Her major interest is clinical and translational research in atopic dermatitis. She is principle investigator in several clinical trials and investigator-initiated studies focused on difficult to treat atopic dermatitis and systemic immunosuppressive and immuno-modulating treatment. For translational, she closely collaborates with the Center of Translational Immunology in Utrecht (Professor Femke van Wijk).

Together with Femke van Wijk, Marjolein de Bruin leads the Utrecht Atopic Dermatitis Research Group.

 

In 2018 she imitated  the BioDay Registry in the Netherlands together with dr. Marie-Louise Schuttelaar from the department of Dermatology of the University Medical Center of Groningen. This register is focused on new systemic treatments in atopic dermatitis and includes a lot of data concerning atopic dermatitis (signs, symptoms, quality of life, work impairment) as well as data concerning atopic co-morbidities. At the end of 2021, 14 centers in the Netherlands are participating in the BioDay Registry and   >1000 patients are included.

 

Marjolein de Bruin-Weller  is a member of the Expertise group Allergy and Eczema Dutch Society of Dermatology and Venereology),  the  European Task Force of Atopic Dermatitis  (ETFAD) , the International Eczema Council (IEC)  and the  GA²LEN ADCARE Task Force.  She is chair of the advisory board Dutch Patient Society for Atopic Dermatitis (VMCE).

 

 

 

Side Activities

External activities (non paid)

Chair Advisory board Dutch patient society for atopic dermatitis (VMCE)

ExComm Member GA²LEN

Member Steering committee of the ADCARE Task Force

Member Dutch Society of Dermatology and Venereology (NVDV)

Member European Academy of Dermatology and Venereology (EADV)

Member European Task Force of Atopic Dermatitis (ETFAD)

Member International Eczema Council (IEC)

Member Horizonscan inflammatory diseases (Zorginstituut Nederland)

Member “ geneesmiddelencommissie FMS”

Chair working group “dure geneesmiddelen” NVDV

 

Collaboration pharmaceutical industry (paid)

International advisory board member:

AbbVie, Almirall, Arena, Aslan, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme

National advisory board member:

AbbVie, Eli Lilly, Galderma, Leo Pharma, Pfizer, and Sanofi-Genzyme

Speaker:

AbbVie, Almirall, Leo Pharma, Eli Lilly, Galderma, Pfizer, Regeneron, and Sanofi- Genzyme

Consultant:

AbbVie, Almirall, Eli Lilly, Galderma, LeoPharma, Pfizer, Regeneron, and Sanofi- Genzyme

 Investigator Initiated Studies:

AbbVie, Leo Pharma, Eli-Lilly, Regeneron and Sanofi-Genzyme

Research Output (156)

Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

Achten Roselie E, Bakker Daphne S, van Luijk Chantal M, van der Wal M Marlot, de Graaf Marlies, van Wijk Femke, Zuithoff Nicolaas P A, van der Rijst Lisa P, Boesjes Celeste M, Thijs Judith L, de Boer Joke H, de Bruin-Weller Marjolein S 16 Mar 2022, In: Clinical and Experimental Allergy. 52 , p. 801-805 5 p.

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis

Achten Roselie E, Van Luijk Chantal, Van der Rijst Lisa, Bakker Daphne, Spekhorst Lotte, Zuithoff Nicolaas, Schuttelaar Marie, Romeijn Geertruida, Voorberg Angelique, Kamsteeg Marijke, Haeck Inge, De Graaf Marlies, Thijs Judith, De Boer Joke, De Bruin-Weller Marjolein 31 Jan 2022, In: Acta Dermato-Venereologica. 102 , p. 1-7

Risk factors for conjunctivitis in atopic dermatitis patients treated with dupilumab: results from the bioday registry

Achten R., Van der Rijst L., Bakker D., Spekhorst L., Boesjes C., Zuithoff N., Knol E., Van Luijk C., De Boer J., Thijs J., De Graaf M., De Bruin-Weller M. Nov 2021, In: Allergy. 76 , p. 11-11

Unraveling heterogeneity in pediatric atopic dermatitis::identification of serum biomarker based patient clusters

Bakker D., de Graaf M., Nierkens S., Delemarre E., Knol E., van Wijk F., de Bruin-Weller M., Drylewicz J., Thijs J. Oct 2021, In: Journal of Investigative Dermatology. 141 , p. S189-S189

Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines:A case series study

Bakker Daphne S., ter Linde José J.M., Amini Mojtaba M., Ariëns Lieneke F.M., van Luijk Chantal M., de Bruin-Weller Marjolein S., Thijs Judith L., Vercoulen Yvonne, van Wijk Femke 4 Sep 2021, In: Allergy. 76 , p. 3814-3817 4 p.

European Task Force on Atopic Dermatitis:position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics

Thyssen J P, Vestergaard C, Barbarot S, de Bruin-Weller M S, Bieber T, Taieb A, Seneschal J, Cork M J, Paul C, Flohr C, Weidinger S, Trzeciak M, Werfel T, Heratizadeh A, Darsow U, Simon D, Torrelo A, Chernyshov P V, Stalder J-F, Gelmetti C, Szalai Z, Svensson Å, von Kobyletzki L B, De Raeve L, Fölster-Holst R, Christen-Zaech S, Hijnen D J, Gieler U, Gutermuth J, Bangert C, Spuls P I, Kunz B, Ring J, Wollenberg A, Deleuran M 7 Mar 2021, In: JEADV : journal of the European Academy of Dermatology and Venereology. 35 , p. e308-e311

Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis

Bakker D S, van der Wal M M, Heeb L E M, Giovannone B, Asamoah M, Delemarre E M, Drylewicz J, Nierkens S, Boyman O, de Bruin-Weller M S, Thijs J L, Wijk F van 18 Feb 2021, In: Journal of Investigative Dermatology. 141 , p. 1943-1953.e13

Treat-to-Target in Atopic Dermatitis:An International Consensus on a Set of Core Decision Points for Systemic Therapies

De Bruin-Weller Marjolein, Biedermann Tilo, Bissonnette Robert, Deleuran Mette, Foley Peter, Girolomoni Giampiero, Hercogová Jana, Hong Chih-Ho, Katoh Norito, Pink Andrew E, Richard Marie-Aleth, Shumack Stephen, Silvestre Juan F, Weidinger Stephan 17 Feb 2021, In: Acta Dermato-Venereologica. 101 , p. 1-7

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis:results from an open-label extension study

Beck Lisa A, Thaçi Diamant, Deleuran Mette, de Bruin-Weller Marjolein, Chen Zhen, Khokhar Faisal A, Zhang Meng, Ozturk Zafer E, Shumel Brad 8 Feb 2021, In: The journal of dermatological treatment. 33 , p. 1608-1616 9 p.

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Bieber T, Thyssen J P, Reich K, Simpson E L, Katoh N, Torrelo A, De Bruin-Weller M, Thaci D, Bissonnette R, Gooderham M, Weisman J, Nunes F, Brinker D, Issa M, Holzwarth K, Gamalo M, Riedl E, Janes J Feb 2021, In: JEADV : journal of the European Academy of Dermatology and Venereology. 35 , p. 476-485 10 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet